AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics (ANGO) PT Cut at Piper Jaffray
January 8, 2016 7:34 AM ESTAngioDynamics (NASDAQ: ANGO) met expectations for its Q2 (Nov) revenues and earnings, but cut guidance for the remainder of the year as the vascular access business has been adjusting to a Q3 recall from last year. Piper Jaffray analyst, Thomas Gunderson, lowered numbers as a result.
The Morpheus product was taken off the market, and the sales force diverted effort to try to retain customers. Not only was retention more... More
